Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357: 1229-37.
Neuman JF. Evaluation and treatment of gynecomastia. Am Fam Physician 1997; 55: 1835-44, 1849-50.
Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy 2012; 32: 1123-40.
Aerts J, Karmochkine M, Raguin G. [Gynecomastia due to pravastatin]. Presse Med 1999; 28: 787. French.
Hammons KB, Edwards RF, Rice WY. Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherapy 2006; 26: 1165-8.
Oteri A, Catania MA, Travaglini R, Russo A, Giustini SE, Caputi AP, et al. Gynecomastia possibly induced by rosuvastatin. Pharmacotherapy 2008; 28: 549-51.
Picolos MK, Zeniou V, Michalis A. Rosuvastatin-induced gynaecomastia. Clin Endocrinol (Oxf) 2010; 73: 421-2.
Roberto G, Biagi C, Montanaro N, Koci A, Moretti U, Motola D. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol 2012; 68: 1007-11.
Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol 2015; 71: 569-78.
Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000; 49: 1234-8.
Santini SA, Carrozza C, Lulli P, Zuppi C, CarloTonolo G, Musumeci S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb 2003; 10: 160-4.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.